Loading
A phase 3 trial testing XZP-3287 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05077449, led by Xuanzhu Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer. Planned enrolment is 300 participants (estimated). The study started in 2021-11-16 and primary completion is expected in 2024-02-22. No results have been posted on ClinicalTrials.gov.